

## Special Issue

# Angiotensin-Converting Enzyme in Health and Diseases

### Message from the Guest Editor

Angiotensin I-converting enzyme (ACE) is a  $\text{Zn}^{2+}$  carboxydipeptidase that plays crucial roles in blood pressure regulation and the development of vascular pathology. Numerous studies have identified ACE as a potent pro-inflammatory modulator that contributes to the recruitment of inflammatory cells into tissues by regulating chemokines and adhesion molecules. Furthermore, ACE not only functions as a cell membrane ectopeptidase but can also be secreted into the extracellular environment by activated myelomonocytic or other lineage cells, acting as a local and systemic regulator of peptides. Given its broad substrate specificity and wide tissue distribution, ACE impacts various biological processes. The well-established association of ACE with immunoinflammatory diseases presents an excellent opportunity for authors and investigators to contribute their original research or review articles to this Special Issue, entitled “Angiotensin-Converting Enzyme in Health and Diseases”. We cordially invite you to share your expertise in ACE function research in this exceptional forum.

### Guest Editor

Dr. Sergei M. Danilov

Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA

### Deadline for manuscript submissions

closed (31 December 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/193632](https://mdpi.com/si/193632)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).